Table 4.

Comparison to other trials of TKI for thyroid cancer

Study medicationResponse rate (%)Progression-free survival (mo)Median survival (mo)
Sunitinib*3112.8NR
Sorafenib (17)2319.3NR
Sorafenib (18)1416/1023/37.5
Axitinib (19)3018.1NR
Motesanib (15)149.2NR
Motesanib (20)211NR

Abbreviation: NR, not reached.

  • *Current study.

  • The study had two arms with different inclusion criteria.

  • The study only included patients with medullary carcinoma.